For the first time, a research team at Lund University in Sweden has successfully reprogrammed mouse and human skin cells into immune cells called dendritic cells.
The process is quick and effective, representing a pioneering contribution for applying direct reprogramming for inducing immunity. Importantly, the finding opens up the possibility of developing novel dendritic cell-based immunotherapies against cancer.
Our so-called dendritic cells function as the immune system’s sentinels. Their task is to scan our tissues for foreign particles, such as bacteria, viruses or cancer cells, and to devour them. They subsequently break down the particles into smaller pieces, known as antigens, and present them on the surface to the immune system’s killer cells (T-cells). In this way, the killer cells learn which infectious agents and cancer cells they are to search for and kill.
Due to these key features, dendritic cell-based strategies have been tested to treat cancer patients. However, cancer can affect the dendritic cells in such a way that they get lost or become dysfunctional. We therefore need to find new ways of generating dendritic cells for every patient. Now, for the first time, a research team in Lund has succeeded in obtaining dendritic cells by a process called direct reprogramming. They have identified three essential proteins (PU.1, IRF8 and BATF3) that are required and sufficient to change the identity of mouse cells to make them become dendritic cells instead. They have also confirmed that the same protein cocktail reprograms human skin-derived cells to dendritic cells. This study is now published and highlighted in the cover of the journal Science Immunology.
“From a tissue section taken from the skin, we can cultivate millions of cells and reprogram them to dendritic cells in a process that takes only nine days”, says Filipe Pereira, the leader of the research team that conducted the study.
“Our study has shown that reprogrammed cells have the ability to effectively capture and present antigens to killer cells in the same way as ‘natural’ dendritic cells.” The researchers can even direct the induced dendritic cells towards a particular target by presenting the right antigen to them in a test tube, before introducing the cells into the organism. This finding opens up future possibilities to develop new strategies for immunotherapy against solid tumours and blood cancers, beyond the treatments currently available.
“This represents an excellent opportunity to merge the fields of cellular reprogramming and cancer immunotherapy. Generating dendritic cells employing direct cell reprogramming is very attractive from a therapeutic perspective: our studies may be useful in the clinic for generation of patient-specific dendritic cells”, according to Filipe Pereira.
Cancer immunotherapy employs the cellular components of a persons’ immune system to fight cancer and it was awarded with the Nobel Prize in Physiology or Medicine this year. By using reprogrammed dendritic cells the probability of rejection by the organism is lower as these cells can be generated from the skin of each individual patient.
“Tumours often undergo a number of mutations, developing into a heterogeneous entity, which makes it more difficult for the immune system to identify them as a threat. In a more creative perspective, we now want to explore the process of dendritic cell reprogramming to develop a cancer gene therapy. We are aiming at injecting the three reprogramming proteins straight into the tumour forcing it to present their own tumour-specific antigens. This allows the activation of the killer cells against tumour cells and may lead to their elimination. We have named this concept TrojanDC in an analogy with Homero’s Trojan horse. The great potential of this technology for cancer treatment lead us to start a new company together with Lund University for the development of this concept into a product that hopefully will reach cancer patients one day”, says Filipe Pereira.
“Additionally, our studies open up the possibility of reprogramming other dendritic cell sub-types taking advantage of their distinct functional features. A better understanding of the mechanisms that determine the identity of immune sentinels and of how to use this knowledge to reprogram other cell types into dendritic cells could make these patient-specific cells useful in the clinic”, concludes Filipe Pereira.
Learn more: WATCH: A code for reprogramming immune sentinels
The Latest on: Immunotherapies
via Google News
The Latest on: Immunotherapies
- 'Exciting Times' With Immunotherapy for Kidney Cancer on February 19, 2019 at 8:56 am
But the new immunotherapies that act on programmed cell death pathways soon made an impact. The combination of nivolumab and ipilimumab was approved by the US Food and Drug Administration, and after s... […]
- How the 'Iron Man' of immune cells helps T cells fight infection on February 19, 2019 at 6:49 am
They are of great interest as the basis of T cell-based vaccination and immunotherapies. The findings were published today in the journal PNAS. Professor Stephen Turner said that while it has been ... […]
- Researcher: New immunotherapies ‘have made a revolution in many, many tumors’ on February 19, 2019 at 6:06 am
The way doctors typically approach kidney cancer treatment could be evolving. Two separate studies published Saturday in the New England Journal of Medicine showed that renal cell cancer patients had ... […]
- Revealed: How the 'Iron Man' of immune cells helps T cells fight infection on February 19, 2019 at 6:05 am
They are of great interest as the basis of T cell-based vaccination and immunotherapies. Now, a study by Monash Biomedicine Discovery Institute (BDI) scientists has revealed the mechanisms by which ot... […]
- Global CD40 Ligand Market Analysis by Global Key Players: Biogen, Inc., Bristol-Myers Squibb Company, eTheRNA Immunotherapies NV and more... on February 18, 2019 at 5:48 am
Feb 18, 2019 (Heraldkeeper via COMTEX) -- The Global CD40 Ligand Market is expected to grow at a high CAGR in the forecast period. The Internet of things is the network of physical devices, vehicles, ... […]
- Global Cancer Immunotherapies Market | New Assays and Applications- Novartis International, GlaxoSmithKline, Celgene Corporation, Seattle Genetics on February 18, 2019 at 3:54 am
Researchmoz added Most up-to-date research on "Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline" to ... […]
- Immunotherapy 'tidal wave' demands interdisciplinary approach on February 16, 2019 at 9:32 am
“In 2018, there were over 900 new cancer immunotherapies in development, with over 5,000 clinical trials investigating these agents and more than half a million patients being treated with these agent... […]
- Global Allergy Immunotherapies Market Will Grow at a CAGR 8.3% and Reach USD 1.73 Billion by 2023, from USD 1.07 Billion in 2017 on January 17, 2019 at 4:00 pm
New Global Allergy Immunotherapies (Allergy Immunotherapy) Consumption Market 2023 Report Covers market forecast and top Companies like ALK-Abello, Stallergenes Greer, Merck, Allergy Therapeutics and ... […]
- bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies on January 7, 2019 at 5:30 am
bluebird bio, Inc. (BLUE) and Inhibrx, Inc. (Inhibrx) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) ... […]
via Bing News